Celgene Commences Thalomid Patent Litigation Against Barr
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawsuit triggers 30-month stay of FDA action on generic thalidomide.
You may also be interested in...
Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer
Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.
Will REMS Delay Generics? Revlimid Petition May Help Determine The Answer
Dr. Reddy’s asks FDA to spell out policy to assure that new Risk Evaluation and Mitigation Strategies will be used to block generics. Celgene’s refusal to make Revlimid available for bioequivalence study is at issue.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.